The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral…
VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapiesPhase 3 data have demonstrated that…